Pcr.Wa
PCR.WA is a specialty chemicals company that produces and sells chemical products, primarily serving industrial and commercial customers.
Business. PCR.WA is a specialty chemicals company that produces and sells chemical products, primarily serving industrial and commercial customers.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
PCR.WA is a specialty chemicals company that produces and sells chemical products, primarily serving industrial and commercial customers.
PCR.WA has a liquidity ratio of 1.47, indicating a moderate ability to cover short-term liabilities with its current assets. The company's cash and equivalents amount to 83.87 million PLN, while its long-term debt stands at 544.70 million PLN, resulting in a negative net cash position after subtracting total debt. The debt-to-equity ratio of 0.4 suggests a relatively conservative capital structure, with equity financing playing a larger role than debt.
In terms of profitability, PCR.WA's return on equity (ROE) is 4.53%, and its return on assets (ROA) is 2.67%. These figures are below the typical thresholds for high-performing specialty chemical firms, indicating that the company is generating relatively modest returns on its equity and asset base.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification may expose the company to higher operational and market risks, particularly in the event of regional economic downturns or supply chain disruptions.
PCR.WA's growth trajectory appears to be modest, with no significant revenue growth reported in the most recent financial period. The company's operating cash flow is 295.93 million PLN, but its free cash flow is negative at -23.14 million PLN, primarily due to capital expenditures of -151.52 million PLN. This suggests that the company is reinvesting heavily in its operations, which could support future growth but may also limit its ability to return capital to shareholders in the short term.
The company's risk profile is characterized by medium liquidity risk and low dilution risk. The negative net cash position after subtracting total debt is a key liquidity flag, and the company has not indicated any immediate plans for equity dilution. However, the negative free cash flow and high capital expenditures may signal potential future liquidity pressures if operating cash flow does not improve.
Recent events, including analyst estimates and recommendations, suggest a generally positive outlook for PCR.WA. The mean price target of 81.78 PLN and a mean recommendation of 1.50 (indicating a "buy" rating) reflect analyst confidence in the company's future performance. However, the absence of "hold" or "sell" ratings suggests a relatively narrow range of opinions among analysts.
- PCR.WA has a conservative capital structure with a debt-to-equity ratio of 0.4, but its negative net cash position raises liquidity concerns.
- The company's ROE of 4.53% and ROA of 2.67% are below industry benchmarks, indicating suboptimal returns on equity and assets.
- PCR.WA's revenue is concentrated in a single business segment, increasing its exposure to market and operational risks.
- The company is investing heavily in capital expenditures, which may support long-term growth but is currently reducing free cash flow.
- Analysts have a generally positive outlook, with a mean price target of 81.78 PLN and a "buy" recommendation.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 6,13 |
| Revenue | —no estimate | —no estimate | 2,0B PLN |
| Operating income | —no estimate | —no estimate | 180,5M PLN |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- PCR.WA Market data — financials · 2026-05-28
- PCC Rokita SA Market data — analyst estimates · 2026-05-28
Ownership & reference
Leadership
- Alfred PelzerChairman of the Supervisory Board